Refarmed Chemicals takes pride in offering pharmaceutical-grade Ciclopirox Olamine, an indispensable antifungal agent in the medical field. Specifically targeting fungal infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and various Candida (yeast) infections, our product showcases a versatile application in creating topical treatments like creams and lotions as well as oral medications and veterinary solutions. Engineered for effectiveness, our Ciclopirox Olamine guarantees a high purity level of 76.0 - 78.5%, ensuring a potent defense against a wide-ranging spectrum of fungal strains. With a broad-spectrum antifungal profile, it is noted for its remarkable efficacy and minimum side effects, making it a well-tolerated choice for patients. This pharmaceutical agent comes in a white to pale yellow crystalline powder form, demonstrating superb solubility in water, alcohol, and chloroform. The CAS number associated with this compound is 41623-74-0, a testament to its consistent and recognized chemical identity. The provided product satisfies rigorous quality checks, with specifications like pH values of 8.0 - 9.0, heavy metals content below 20 ppm, loss on drying under 1.5%, and a sulfated ash content not exceeding 0.1%. Administered typically in a twice-daily regimen, the antifungal should be applied with caution, avoiding use by individuals with known allergies to the compound as well as contact with open wounds or broken skin. To ensure optimal results and patient safety, any occurrence of skin irritation should prompt immediate consultation with healthcare professionals. Presented in a concise yet comprehensive datasheet, our Ciclopirox Olamine is a testament to Refarmed Chemicals' dedication to the advancement of pharmaceutical care, offering a high-quality solution for antifungal needs. The described product is a vital component in the armamentarium against challenging fungal infections, bolstering our commitment to delivering growth in the industry and beyond.
Products still subject to third-party patent protection might be available solely for R&D purposes.
